CYTOKINETICS INC 8-K

What Happened

• Cytokinetics, Incorporated filed an 8-K disclosing an underwriting agreement dated May 6, 2026, for a public offering of 9,859,155 shares of common stock at $71.00 per share.
• The underwriters (Morgan Stanley, Goldman Sachs, J.P. Morgan and Jefferies) had a 30‑day option to purchase up to 1,478,873 additional shares, which they exercised in full on May 7, 2026.
• After underwriting discounts, commissions and estimated offering expenses, the Company reports net proceeds of approximately $760.2 million. The offering was made under the Company’s automatic shelf registration statement on Form S-3 (filed Feb 27, 2025); a final prospectus supplement was filed May 7, 2026. A legal opinion from Gibson, Dunn & Crutcher LLP regarding validity of the shares is filed as an exhibit.

Key Details

• Shares offered: 9,859,155 common shares at $71.00 per share.
• Overallotment exercised: 1,478,873 additional shares (exercised May 7, 2026).
• Net proceeds to Cytokinetics: ~ $760.2 million (after fees and expenses).
• Lead underwriters: Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Jefferies LLC.

Why It Matters

• The offering materially increases Cytokinetics’ cash resources (≈ $760M), which the company can use for operations, development programs or other corporate purposes reported in future disclosures.
• Issuing nearly 11.34M shares (base plus overallotment) increases the company’s outstanding shares and can dilute existing shareholders’ ownership and per-share metrics such as EPS.
• Investors should watch subsequent company disclosures for details on the use of proceeds, and monitor share count and trading activity following the offering.